![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhQnp1Ee3DhRqNZWP85f34rXGkDDoxhCHTgOLeHitM3-ZsuKTlgQ4qSvfUmi5BykRe_S1w440lm8Xh0HAeBTcke-nmzP446T5BHWXHMyucqXaFhvUMSQ81Xbf4A8TZoR4k9fFEHhoMpT2Y/s1600/MDWD+2014-03+IPO.png)
Description
MediWound Ltd. is a fully integrated biopharmaceutical company. The Company is focused on developing, manufacturing and commercializing products to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds and connective tissue disorders. The Company’s biopharmaceutical product, NexoBrid, which is based on its patented proteolytic enzyme technology, represents a new paradigm in burn care management, and its clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier upon patient admission, without harming viable tissues. The Company launched NexoBrid in December 2013 in the European Union through its wholly-owned German subsidiary, targeting a focused audience of burn specialists treating patients in burn centers and hospital burn units.
Address
42 Hayarkon Street, Industrial Zone
YAVNE, ZF 8122745
Israel
YAVNE, ZF 8122745
Israel
No comments:
Post a Comment